SecBot SecBot
Biotech Drug Report Generated Nov 12, 2026

HEPZATO KIT

DCTH·DELCATH SYSTEMS, INC.
BULLISH
Drug Impact Rating4/10
Trial phase
Approved (FDA)
Time to market
Already on the market. FDA-approved August 2023, currently generating commercial revenue.
Why 4/10
HEPZATO KIT is already FDA-approved and commercially launched with no pending regulatory decision (PDUFA). The next hard, dated catalysts are quarterly earnings reports, which are not binary events. The Phase 2 breast cancer trial is too early (first patient dosed July 2026) for a pivotal readout within 12 months. As an approved, revenue-generating product at a company with a market cap that reflects its commercial trajectory, the impact score is 4.
Actionable Insight BULLISH

With no binary FDA catalyst ahead, the stock's near-term direction hinges on commercial execution: watch Q4 2026 earnings (expected early 2027) for continued HEPZATO KIT revenue growth and treatment center expansion. The Phase 2 breast cancer trial is an important long-term value driver but is unlikely to produce pivotal data within 12 months. The stock's 52-week high near $22.32 and strong institutional accumulation suggest the market is already pricing in the current growth trajectory.

Price Chart

Loading chart...

Executive Summary

HEPZATO KIT is Delcath Systems' FDA-approved liver-directed therapy for metastatic uveal melanoma, delivering high-dose melphalan chemotherapy directly to the liver via a proprietary perfusion system. Approved in August 2023, it is the first and only FDA-approved liver-directed treatment for its indication and is generating rapidly growing commercial revenue ($32.7M in Q3 2026, up 70% YoY). The company raised full-year 2026 guidance to $115M-$117M, has strong institutional backing (BlackRock, Vanguard), and a bullish analyst consensus (11 buy/strong buy vs 1 hold, mean price target $28.60). A Phase 2 trial in liver-dominant metastatic breast cancer is underway but early-stage. The stock trades near its 52-week high of $22.32.

How It Works

HEPZATO KIT delivers the chemotherapy drug melphalan directly to the liver through a catheter, while a filtration system isolates the liver's blood supply to prevent the drug from circulating throughout the body. This approach (called percutaneous hepatic perfusion, or PHP) allows a much higher dose of chemotherapy to reach liver tumors than would be possible with standard intravenous delivery, while reducing side effects elsewhere in the body.

Trial Status

HEPZATO KIT was FDA-approved on August 14, 2023 as the first liver-directed therapy for unresectable hepatic-dominant metastatic uveal melanoma. It is commercially available in the U.S. through a network of over 31 active treatment centers. A Phase 2 clinical trial for liver-dominant metastatic breast cancer began dosing patients in July 2026. The European version (CHEMOSAT) was included in ESMO-EURACAN clinical practice guidelines for uveal melanoma in April 2026.

The Two-Sided Case

▲ Bull Case7
First-mover advantage: HEPZATO KIT is the only FDA-approved liver-directed therapy for unresectable metastatic uveal melanoma, a niche with no direct FDA-approved competitor.
Strong commercial momentum: Q3 2026 HEPZATO KIT revenue of $32.7M grew ~70% YoY, with full-year 2026 guidance raised to $115M-$117M, implying continued rapid adoption.
Expanding treatment network: 31+ active U.S. centers with a target of 36+ by year-end 2026, driving volume growth of at least 41% over 2025.
Institutional accumulation: BlackRock added 51.7% to its position in Q2 2026, and multiple other funds (Barclays, BNP Paribas, ExodusPoint) doubled or added positions in Q2 and Q3 2026.
Analyst support: 11 of 12 analysts rate the stock Buy or Strong Buy, with a mean price target of $28.60 (31.6% upside from $21.74).
Pipeline optionality: Phase 2 trial in liver-dominant metastatic breast cancer could open a much larger addressable market if successful.
CMS NTAP and permanent J-code (J9248) support hospital reimbursement and adoption.
▼ Bear Case7
Narrow approved indication: The current label is limited to unresectable hepatic-dominant metastatic uveal melanoma with less than 50% liver involvement, a relatively small patient population.
Procedure complexity: HEPZATO requires specialized interventional radiology infrastructure and trained staff, limiting the addressable treatment centers and creating a barrier to rapid expansion.
Safety profile: The FDA label carries a boxed warning for peri-procedural complications including hemorrhage, hepatocellular injury, and thromboembolic events, plus myelosuppression. The drug is only available through a restricted REMS program.
Competition from systemic therapies: Tebentafusp (Kimmtrak) and checkpoint inhibitors (ipilimumab/nivolumab) are alternative treatment options for metastatic uveal melanoma.
Operating costs rising: As noted in Q2 2026 analysis, the cost of running the business has been climbing alongside revenue growth, which could pressure margins.
Phase 2 breast cancer trial is early-stage and unproven; success is far from guaranteed.
Stock has already appreciated significantly (52-week range $8.12-$22.32), with much of the commercial success potentially priced in.

Upcoming Catalysts

  • Q4 2026 earnings report (early 2027) - commercial revenue growth trajectory
  • Phase 2 breast cancer trial interim data readout (timing uncertain, likely 2027+)
  • Expansion of active treatment centers (targeting 36+ by end of 2026)
  • Potential label expansion into additional liver-dominant cancer indications

Source Filing

The SecBot filing or press-release report that triggered this drug report:

DELCATH SYSTEMS, INC. 8-K DCTH ·Originating report

Sources · 10

Hover a chip for the title
1 medpagetoday.com2 kdvr.com3 biospace.com4 msn.com5 curetoday.com6 businesswire.com7 morningstar.com8 morningstar.com9 seekingalpha.com10 sec.gov